What is xeroderma pigmentosum?
Xeroderma pigmentosum (XP) is a very rare skin disorder where a person is highly sensitive to sunlight (photosensitive), has premature skin aging and is prone to developing skin cancers. This is caused by a cellular hypersensitivity to ultraviolet (UV) light as a result of a defect in the DNA repair system.
What causes xeroderma pigmentosum?
Xeroderma pigmentosum is an autosomally recessive inherited disease, which means there are two recessive xeroderma pigmentosum genes (one from each parent). If parents are carriers of the xeroderma pigmentosum trait (ie they each have one xeroderma pigmentosum gene and one normal gene), they will not show signs or symptoms of the disease. At least 7 different gene abnormalities or complementation groups have been described in different families (XPA to XPG) resulting in varying disease severity.
The signs and symptoms of xeroderma pigmentosum are a result of an impaired DNA repair system. In people who do not have xeroderma pigmentosum, cell damage from UV light is mended by the DNA repair system. However, people with xeroderma pigmentosum have a defect in this repair system and any damaged cells from UV light remain unrepaired, leading to cancerous cells or cell death.
Who is at risk of xeroderma pigmentosum?
If both parents are carriers of the xeroderma pigmentosum trait, they have a greater risk of producing a child with xeroderma pigmentosum. Parents that already have a child with xeroderma pigmentosum have a 1 in 4 chance of having another affected child.
Xeroderma pigmentosum occurs worldwide and affects people of all races. Males and females alike can have the condition.
What are the signs and symptoms of xeroderma pigmentosum?
The disease usually progresses through 3 stages. The skin appears normal at birth. The first stage of xeroderma pigmentosum occurs around 6 months after birth with the following signs:
- Areas exposed to the sun such as the face show a reddening of the skin with scaling and freckling. Irregular dark spots may also begin to appear
- These skin changes progress the neck and lower legs. In severe cases the trunk may be involved
- Dry skin is usual
- Over the winter months these changes may diminish
Continued sun exposure leads to the second stage, which is characterised by poikiloderma. There are irregular patches of lightened or darkened skin, a spider web-like collection of blood spots and vessels are seen through the skin, and there is thinning of the skin.
The third stage is the development of actinic keratoses and skin cancers. These may occur as early as age 4–5 years and are more prevalent in sun-exposed areas such as the face. They can also occur in less sun exposed sites, including inside the mouth (eg the tip of the tongue). The common skin cancers are:
Eye problems occur in nearly 80% of xeroderma pigmentosum patients. They may lead to blindness.
- Eyes become painfully sensitive to the sun (photophobia).
- Eyes easily irritated, bloodshot and clouded. Conjunctivitis may occur.
- Non-cancerous and cancerous growths on the eyes may occur.
Neurological problems occur in about 20% of xeroderma pigmentosum patients.
- These can be mild or severe and include spasticity, poor coordination, developmental delay, deafness, and short stature.
- They may develop in late childhood or adolescence. Once they do occur they tend to worsen over time.
How is xeroderma pigmentosum diagnosed?
Usually xeroderma pigmentosum is detected in early infancy, around 1–2 years.
A child presenting with severe sunburn after their first exposure to sun may be a clue to the diagnosis of xeroderma pigmentosum. Xeroderma pigmentosum can usually be conclusively diagnosed by measuring the DNA repair factor from skin or blood samples.
What is the treatment for xeroderma pigmentosum?
There is no cure for xeroderma pigmentosum. The main goal of treatment is absolutely strict protectection from UV exposure. The aim is to prevent the damaging effects UV can have on the skin. Xeroderma pigmentosum patients should follow these general precautionary measures:
- Sun avoidance methods
- Wear protective clothing (long sleeves and pants, shirts with collars, tightly woven fabrics that don't let light through), hats (wide-brimmed) and eyewear (specifically made to protect from UV rays)
- Use sunscreens with SPF of 30 or greater: apply to all exposed areas
- Minimise daytime outdoor activities and ensure full skin cover when outdoors
- Restrict outdoor activities to night time
- Undergo frequent skin examinations by someone who has been taught to recognise signs of skin cancer. Report to your doctor any suspicious spots or growths immediately.
- Examination by a dermatologist at least every 3–6 months. Any suspicious growths can be biopsied. Skin cancers are usually excised.
- Frequent eye examinations by an ophthalmologist.
- Yearly testing (through to age 20) for potential neurological problems.
Actinic keratoses may be treated by cryotherapy, 5-fluorouracil cream or other topical agents. Some xeroderma pigmentosum patients that have had many skin cancers may be prescribed isotretinoin. This is a vitamin A derivative that may prevent formation of new cancers.
What is the prognosis?
Many patients with xeroderma pigmentosum die at an early age from skin cancers. However, if a person is diagnosed early, does not have severe neurological symptoms or has a mild variant, and takes all the precautionary measures to avoid exposure to UV light, they may survive beyond middle age.
Patients with xeroderma pigmentosum and their families will face many challenges in daily living. Strict protection from sunlight is paramount to the management of xeroderma pigmentosum.
- OMIM – Online Mendelian Inheritance in Man (search term Xeroderma pigmentosum)
- Xeroderma Pigmentosum – GeneTests GeneReviews
On DermNet NZ:
- Xeroderma Pigmentosum – Medscape Reference
- Xeroderma pigmentosum US National Library of Medicine Genetics Home Reference
- XP Support Group (UK)
- Xeroderma Pigmentosum Society, Inc. (USA)
- XP Family Support Group (USA)
- Skin Cancer Scientist Sees Ray of Hope A Conversation with James Cleaver By Jeff Miller, University of California, San Francisco
- Helping xeroderma pigmentosum children in Tunisia